Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial
Titel:
Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial
Auteur:
Miller, P.D. Hattersley, G. Lau, E. Fitzpatrick, L.A. Harris, A.G. Williams, G.C. Hu, M.-Y. Riis, B.J. Russo, L. Christiansen, C.